SCYNEXIS

$4.75
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.17 (-3.46%) Today
$0.00 (0.00%) As of 8:00 PM EDT after-hours

Why Robinhood?

You can buy or sell SCYNEXIS and other stocks, options, and ETFs commission-free!

About SCYX

SCYNEXIS, Inc. Common Stock, also called SCYNEXIS, is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. Read More The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ. The listed name for SCYX is SCYNEXIS, Inc. Common Stock.

Employees
27
Headquarters
Jersey City, New Jersey
Founded
1999
Market Cap
50.36M
Price-Earnings Ratio
Dividend Yield
Average Volume
133.18K
High Today
$5.05
Low Today
$4.71
Open Price
$4.92
Volume
64.55K
52 Week High
$14.40
52 Week Low
$4.20

Collections

SCYX Earnings

-$1.19
-$0.79
-$0.40
$0.00
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Q1 2020
Q2 2020
Q3 2020
Estimated
per share
Actual
Expected Nov 9, Pre-Market

You May Also Like